NasdaqCM - Delayed Quote USD
Exact Sciences Corporation (EXAS)
At close: November 15 at 4:00 PM EST
After hours: November 15 at 7:51 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,692,328.00
2,499,766.00
2,084,279.00
1,767,087.00
1,491,391.00
Cost of Revenue
727,800.00
654,200.00
574,400.00
458,757.00
354,300.00
Gross Profit
1,964,528.00
1,845,566.00
1,509,879.00
1,308,330.00
1,137,091.00
Operating Expense
2,173,351.00
2,059,915.00
2,087,412.00
2,143,798.00
1,695,104.00
Operating Income
-208,823.00
-214,349.00
-577,533.00
-835,468.00
-558,013.00
Net Non Operating Interest Income Expense
-35,558.00
-29,771.00
-19,634.00
-18,606.00
-17,122.00
Other Income Expense
33,884.00
42,416.00
-35,394.00
11,568.00
-253,911.00
Pretax Income
-210,571.00
-201,746.00
-632,570.00
-842,506.00
-829,063.00
Tax Provision
3,467.00
2,403.00
-9,064.00
-246,881.00
-5,458.00
Net Income Common Stockholders
-214,038.00
-204,149.00
-623,506.00
-595,625.00
-823,605.00
Diluted NI Available to Com Stockholders
-214,038.00
-204,149.00
-623,506.00
-595,625.00
-823,605.00
Basic EPS
-1.16
-1.13
-3.54
-3.48
-5.61
Diluted EPS
-1.16
-1.13
-3.54
-3.48
-5.61
Basic Average Shares
183,148.50
180,144.00
176,351.00
171,348.00
151,137.00
Diluted Average Shares
183,148.50
180,144.00
176,351.00
171,348.00
151,137.00
Total Operating Income as Reported
-240,193.00
-215,012.00
-593,511.00
-855,678.00
-767,696.00
Total Expenses
2,901,151.00
2,714,115.00
2,661,812.00
2,602,555.00
2,049,404.00
Net Income from Continuing & Discontinued Operation
-214,038.00
-204,149.00
-623,506.00
-595,625.00
-823,605.00
Normalized Income
-240,806.36
-237,657.64
-588,572.12
-603,803.58
-571,217.47
Interest Expense
30,264.00
24,421.00
13,907.00
12,879.00
11,819.00
Net Interest Income
-35,558.00
-29,771.00
-19,634.00
-18,606.00
-17,122.00
EBIT
-180,307.00
-177,325.00
-618,663.00
-829,627.00
-817,244.00
EBITDA
35,577.00
29,283.00
-421,105.00
-649,281.00
-653,882.00
Reconciled Cost of Revenue
606,284.00
539,752.00
474,292.00
373,412.00
284,336.00
Reconciled Depreciation
215,884.00
206,608.00
197,558.00
180,346.00
163,362.00
Net Income from Continuing Operation Net Minority Interest
-214,038.00
-204,149.00
-623,506.00
-595,625.00
-823,605.00
Total Unusual Items Excluding Goodwill
33,884.00
42,416.00
-35,394.00
11,568.00
-253,911.00
Total Unusual Items
33,884.00
42,416.00
-35,394.00
11,568.00
-253,911.00
Normalized EBITDA
1,693.00
-13,133.00
-385,711.00
-660,849.00
-399,971.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
7,115.64
8,907.36
-460.12
3,389.42
-1,523.47
12/31/2020 - 2/1/2001
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
GH Guardant Health, Inc.
29.11
-3.64%
NTRA Natera, Inc.
146.06
-3.34%
ILMN Illumina, Inc.
135.05
-5.05%
TWST Twist Bioscience Corporation
36.89
-5.31%
GRAL GRAIL, Inc.
14.80
-6.39%
VCYT Veracyte, Inc.
35.94
-2.97%
RDNT RadNet, Inc.
79.58
-1.83%
TMO Thermo Fisher Scientific Inc.
513.08
-3.74%
DHR Danaher Corporation
230.50
-3.71%
CRL Charles River Laboratories International, Inc.
187.74
-4.65%